Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Working Capital Changes: 2013-2025

Historic Other Working Capital Changes for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $10.6 million.

  • KalVista Pharmaceuticals' Other Working Capital Changes rose 625.83% to $10.5 million in Q2 2025 from the same period last year, while for Apr 2025 it was $10.6 million, marking a year-over-year increase of 1871.00%. This contributed to the annual value of $10.6 million for FY2025, which is 1862.45% up from last year.
  • According to the latest figures from FY2025, KalVista Pharmaceuticals' Other Working Capital Changes is $10.6 million, which was up 1,862.45% from $538,000 recorded in FY2024.
  • KalVista Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $10.6 million during FY2025, with a 5-year trough of -$6.7 million in FY2023.
  • For the 3-year period, KalVista Pharmaceuticals' Other Working Capital Changes averaged around $1.5 million, with its median value being $538,000 (2024).
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Other Working Capital Changes soared by 3,703.28% in 2022, and later crashed by 172.09% in 2023.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Other Working Capital Changes stood at $244,000 in 2021, then soared by 3,703.28% to $9.3 million in 2022, then plummeted by 172.09% to -$6.7 million in 2023, then spiked by 108.04% to $538,000 in 2024, then soared by 1,862.45% to $10.6 million in 2025.